These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12553481)

  • 21. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
    Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
    Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.
    Stevens RC; Rodman JH; Yong FH; Carey V; Knupp CA; Frenkel LM
    AIDS Res Hum Retroviruses; 2000 Mar; 16(5):415-21. PubMed ID: 10772527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults.
    Rhee EG; Rizk ML; Brainard DM; Gendrano IN; Jin B; Wenning LA; Wagner JA; Iwamoto M
    Antivir Ther; 2014; 19(6):619-24. PubMed ID: 24608069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance of didanosine as enteric-coated capsules versus buffered tablets.
    Barreiro P; Corbatón A; Núñez M; González-Lahoz J; Soriano V
    AIDS Patient Care STDS; 2004 Jun; 18(6):329-31. PubMed ID: 15294082
    [No Abstract]   [Full Text] [Related]  

  • 26. Update on didanosine.
    Cooper DA
    J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):15-25. PubMed ID: 12942665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
    Shelton MJ; Mei H; Hewitt RG; Defrancesco R
    Antimicrob Agents Chemother; 2001 Jan; 45(1):298-300. PubMed ID: 11120981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
    Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic profiling and bioequivalence assessment of two marketed brands of nevirapine tablets in healthy Indian volunteers.
    Narang VS; Lulla A; Malhotra G; Purandare S
    Arzneimittelforschung; 2005; 55(10):598-603. PubMed ID: 16294506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Verweij C; van Rossum AM; Verweel G; Hartwig NG; de Groot R; Burger DM
    J Antimicrob Chemother; 2004 Dec; 54(6):1152-4. PubMed ID: 15537694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.
    Wang Y; Livingston E; Patil S; McKinney RE; Bardeguez AD; Gandia J; O'Sullivan MJ; Clax P; Huang S; Unadkat JD
    J Infect Dis; 1999 Nov; 180(5):1536-41. PubMed ID: 10515813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.
    Damle BD; Mummaneni V; Kaul S; Knupp C
    Antimicrob Agents Chemother; 2002 Feb; 46(2):385-91. PubMed ID: 11796346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The power of simplicity.
    Lange J
    Int J STD AIDS; 2003 Oct; 14 Suppl 1():15-9. PubMed ID: 14617399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo absorption of didanosine formulated in pellets composed of chitosan microspheres.
    Severino P; Da Silva CF; Dalla Costa TC; Silva H; Chaud MV; Santana MH; Souto EB
    In Vivo; 2014; 28(6):1045-50. PubMed ID: 25398797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
    Bonn M; Eydeler U; Barkworth M; Rovati LC
    Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved gastrointestinal tolerance and palatability of didanosine in adults by the use of pediatric power formulation.
    Dodge RT; Shipp KW; Miralles GD
    J Assoc Nurses AIDS Care; 1998; 9(5):27-31. PubMed ID: 9742478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
    McKinney RE; Rodman J; Hu C; Britto P; Hughes M; Smith ME; Serchuck LK; Kraimer J; Ortiz AA; Flynn P; Yogev R; Spector S; Draper L; Tran P; Scites M; Dickover R; Weinberg A; Cunningham C; Abrams E; Blum MR; Chittick GE; Reynolds L; Rathore M;
    Pediatrics; 2007 Aug; 120(2):e416-23. PubMed ID: 17646352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tenofovir on didanosine absorption in patients with HIV.
    Pecora Fulco P; Kirian MA
    Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.